PH12022500029A1 - Anti-pd-1 antibodies and fusion proteins - Google Patents

Anti-pd-1 antibodies and fusion proteins

Info

Publication number
PH12022500029A1
PH12022500029A1 PH1/2022/500029A PH12022500029A PH12022500029A1 PH 12022500029 A1 PH12022500029 A1 PH 12022500029A1 PH 12022500029 A PH12022500029 A PH 12022500029A PH 12022500029 A1 PH12022500029 A1 PH 12022500029A1
Authority
PH
Philippines
Prior art keywords
methods
antibodies
fusion proteins
cell
binding
Prior art date
Application number
PH1/2022/500029A
Other languages
English (en)
Inventor
Tzu-Pei Chang
Dan Lu
Stella A Martomo
Faical Miyara
Jeegar Patel
Zhanna Polonskaya
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of PH12022500029A1 publication Critical patent/PH12022500029A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2022/500029A 2020-06-23 2021-06-23 Anti-pd-1 antibodies and fusion proteins PH12022500029A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043114P 2020-06-23 2020-06-23
US202063111459P 2020-11-09 2020-11-09
PCT/US2021/038740 WO2021262880A2 (en) 2020-06-23 2021-06-23 Anti-pd-1 antibodies and fusion proteins

Publications (1)

Publication Number Publication Date
PH12022500029A1 true PH12022500029A1 (en) 2024-04-22

Family

ID=79282816

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/500029A PH12022500029A1 (en) 2020-06-23 2021-06-23 Anti-pd-1 antibodies and fusion proteins

Country Status (13)

Country Link
US (4) US20230416363A1 (enExample)
EP (3) EP4729531A3 (enExample)
JP (2) JP7644151B2 (enExample)
KR (1) KR20230027267A (enExample)
CN (1) CN116194471A (enExample)
AU (1) AU2021296437A1 (enExample)
BR (1) BR112022025632A2 (enExample)
CA (1) CA3184746A1 (enExample)
CO (1) CO2022018053A2 (enExample)
IL (1) IL299238A (enExample)
MX (1) MX2022016588A (enExample)
PH (1) PH12022500029A1 (enExample)
WO (1) WO2021262880A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白
CN116333155A (zh) * 2023-03-09 2023-06-27 杭州美赛生物医药科技有限公司 靶向pd-1和vegf的双功能抑制剂
WO2025048616A1 (ko) * 2023-08-31 2025-03-06 주식회사 지아이셀 Il-2 단백질 및 il-15 단백질의 키메라 단백질 또는 변이체, 이를 포함하는 융합단백질, 및 이를 발현하는 유전자 조작된 세포
WO2025217310A1 (en) * 2024-04-10 2025-10-16 Prolynx Llc Pegylated il- 15 receptor alpha cytokines
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用
WO2026161860A1 (en) * 2025-01-27 2026-07-30 Kadmon Corporation, Llc Dosing of immunocytokines for cancer treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE329263T1 (de) * 1998-10-30 2006-06-15 Jonathan L Miller Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
GB0816461D0 (en) * 2008-09-09 2008-10-15 Univ Manchester Biomass
WO2011130417A2 (en) * 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
LT2748201T (lt) * 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
HK1200850A1 (en) * 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
WO2014023709A1 (en) * 2012-08-09 2014-02-13 Roche Glycart Ag Asgpr antibodies and uses thereof
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
US8945560B1 (en) * 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
LT3094351T (lt) * 2014-01-15 2022-04-11 Kadmon Corporation, Llc Imunitetą moduliuojantys agentai
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AU2016326575A1 (en) * 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
EP3455254B1 (en) * 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
KR102048476B1 (ko) * 2016-08-05 2019-11-26 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
LT3535298T (lt) * 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
CA3097593A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
CN116194471A (zh) 2020-06-23 2023-05-30 卡德门企业有限公司 抗pd-1抗体和融合蛋白

Also Published As

Publication number Publication date
CA3184746A1 (en) 2021-12-30
EP4610275A3 (en) 2025-12-03
EP4168124A2 (en) 2023-04-26
US12612460B2 (en) 2026-04-28
JP7644151B2 (ja) 2025-03-11
IL299238A (en) 2023-02-01
CO2022018053A2 (es) 2022-12-20
US20250136693A1 (en) 2025-05-01
US20260176362A1 (en) 2026-06-25
US20230416363A1 (en) 2023-12-28
JP2025091418A (ja) 2025-06-18
MX2022016588A (es) 2023-03-15
WO2021262880A2 (en) 2021-12-30
AU2021296437A1 (en) 2023-02-23
BR112022025632A2 (pt) 2023-01-17
US20260217831A1 (en) 2026-07-30
KR20230027267A (ko) 2023-02-27
EP4729531A2 (en) 2026-04-22
EP4610275A2 (en) 2025-09-03
WO2021262880A3 (en) 2022-02-17
EP4729531A3 (en) 2026-07-15
CN116194471A (zh) 2023-05-30
EP4168124A4 (en) 2024-10-02
JP2023531920A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
MX2022016588A (es) Anticuerpos anti-pd-1 y proteinas de fusion.
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MY205758A (en) Anti-nkg2a antibodies and uses thereof
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
Cessak et al. TNF inhibitors—mechanisms of action, approved and off-label indications
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
WO2016191643A4 (en) Tigit-binding agents and uses thereof
MY209387A (en) Multi-specific binding proteins for cancer treatment
SI1527100T1 (sl) Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
US11945863B2 (en) CD33-, CD16- and CD123-specific single chain triplebody
ZA202212133B (en) Anti-cd200r1 antibodies and methods of use thereof
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
WO2021231741A3 (en) Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins
ZA202110285B (en) Antibodies and methods of use
EA202190807A1 (ru) Антитела к синуклеину
MX2023005386A (es) Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
US20180030124A1 (en) Methods and compositions for enhancing anti-ssea4 immunotherapy
PH12022550671A1 (en) Antigen binding proteins
WO2021043810A8 (en) Anti-fucosyl-gm1 antibodies
EA202092672A1 (ru) Антитела против dll3 и их применения
MX2024006573A (es) Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.